Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial - Sircar, Geetabali; Goswami, Rudra Prosad; Sircar, Dipankar; Ghosh, Alakendu; Ghosh, Parasar (Rheumatology (Oxford, England), 2018)
Keywords: Adult; Antirheumatic Agents - therapeutic use; Cyclophosphamide - therapeutic use; Disease Progression; Female; Humans; Lung - pathology; Lung Diseases, Interstitial - drug therapy; Lung Diseases, Interstitial - etiology; Male; Rituximab - therapeutic use; Scleroderma, Diffuse - complications; Scleroderma, Diffuse - drug therapy; Scleroderma, Diffuse - pathology; Severity of Illness Index; Skin - pathology; Treatment Outcome; Vital Capacity - drug effects; Walk Test; cyclophosphamide; interstitial lung disease; modified Rodnan skin score; diffuse systemic sclerosis; rituximab; forced vital capacity